EverGlade Aids Landmark Bio in Securing $18.3 Million for Innovative Therapy Manufacturing
On April 16, 2026, EverGlade, a leading advisory firm specializing in federal funding strategy, announced its successful collaboration with Landmark Bio in securing up to $18.3 million from the Advanced Research Projects Agency-Health (ARPA-H) through its TRANSFORM-EV initiative. This transformative grant aims to develop a groundbreaking continuous manufacturing platform for extracellular vesicles (EVs), thereby improving the efficiency and scalability of their production.
The funding underscores the growing importance of EVs in the realm of advanced therapies, including viral vectors and cell therapies. These innovative therapeutic approaches are paving the way for a new era in treatment options for various health conditions. With the financial backing from ARPA-H, Landmark Bio plans to revolutionize the current batch-based production methods, which are often limited by low yields and high costs.
Gregg Nyberg, the Chief Technology Officer at Landmark Bio, expressed his appreciation for EverGlade's assistance during the negotiation process. He emphasized how EverGlade played a pivotal role in refining the project’s statement of work, financials, and milestones. "EverGlade was a huge help as we worked through negotiations with the government. Their expertise was essential to align our goals and present a solid case for funding," Nyberg stated.
The TRANSFORM-EV program particularly focuses on enabling access to transformative therapies through the continuous manufacturing of extracellular vesicles. Landmark Bio’s approach aims to integrate advanced upstream and downstream manufacturing technologies within a three-year timeframe, ultimately aiming to broaden the global accessibility of EV-based therapeutics.
Giacomo Apadula, CEO of EverGlade, highlighted the significance of this award not only for Landmark Bio but also for the scientific community as a whole. He conveyed his enthusiasm for the project, stating, "We couldn't be more excited for Landmark Bio and for the scientific community as a whole for this award. This program represents a meaningful step forward in advancing scalable manufacturing for next-generation therapeutics, and we're proud to support the Landmark Bio team as they move into the execution phase."
EverGlade has built a reputation for facilitating federal funding processes, guiding its clients through every phase from early-stage strategy and proposal development to negotiations and post-award execution. The firm’s contributions extend across various federal agencies including ARPA-H, BARDA, and DARPA, presenting innovators in the healthcare and biotechnology fields with invaluable support.
Originating from Watertown, Massachusetts, Landmark Bio is an entity under Artis BioSolutions, specializing in integrated capabilities that streamline the development and manufacturing processes of advanced therapies and emerging biotechnologies. By combining process development, advanced analytics, and good manufacturing practices (GMP), the company aims to bridge the gap between revolutionary scientific discoveries and their clinical applications.
Looking forward, both EverGlade and Landmark Bio are set to leverage their partnership further to maximize the potential of this significant funding, with the aim of delivering impactful health solutions to patients in need. As the biomedical landscape evolves, collaborations like this one are vital for translating cutting-edge science into real-world healthcare solutions.
The funding underscores the growing importance of EVs in the realm of advanced therapies, including viral vectors and cell therapies. These innovative therapeutic approaches are paving the way for a new era in treatment options for various health conditions. With the financial backing from ARPA-H, Landmark Bio plans to revolutionize the current batch-based production methods, which are often limited by low yields and high costs.
Gregg Nyberg, the Chief Technology Officer at Landmark Bio, expressed his appreciation for EverGlade's assistance during the negotiation process. He emphasized how EverGlade played a pivotal role in refining the project’s statement of work, financials, and milestones. "EverGlade was a huge help as we worked through negotiations with the government. Their expertise was essential to align our goals and present a solid case for funding," Nyberg stated.
The TRANSFORM-EV program particularly focuses on enabling access to transformative therapies through the continuous manufacturing of extracellular vesicles. Landmark Bio’s approach aims to integrate advanced upstream and downstream manufacturing technologies within a three-year timeframe, ultimately aiming to broaden the global accessibility of EV-based therapeutics.
Giacomo Apadula, CEO of EverGlade, highlighted the significance of this award not only for Landmark Bio but also for the scientific community as a whole. He conveyed his enthusiasm for the project, stating, "We couldn't be more excited for Landmark Bio and for the scientific community as a whole for this award. This program represents a meaningful step forward in advancing scalable manufacturing for next-generation therapeutics, and we're proud to support the Landmark Bio team as they move into the execution phase."
EverGlade has built a reputation for facilitating federal funding processes, guiding its clients through every phase from early-stage strategy and proposal development to negotiations and post-award execution. The firm’s contributions extend across various federal agencies including ARPA-H, BARDA, and DARPA, presenting innovators in the healthcare and biotechnology fields with invaluable support.
Originating from Watertown, Massachusetts, Landmark Bio is an entity under Artis BioSolutions, specializing in integrated capabilities that streamline the development and manufacturing processes of advanced therapies and emerging biotechnologies. By combining process development, advanced analytics, and good manufacturing practices (GMP), the company aims to bridge the gap between revolutionary scientific discoveries and their clinical applications.
Looking forward, both EverGlade and Landmark Bio are set to leverage their partnership further to maximize the potential of this significant funding, with the aim of delivering impactful health solutions to patients in need. As the biomedical landscape evolves, collaborations like this one are vital for translating cutting-edge science into real-world healthcare solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.